RTSM Randomization and Trial Supply Software: Custom Build Versus Suvoda and 4G Clinical

What Suvoda, 4G Clinical and Endpoint Clinical do well

A patient is in the chair in Warsaw and the coordinator needs an assignment now. That single second of pressure is why randomization and trial supply management, usually shortened to RTSM and sometimes called interactive response technology, is treated as safety critical spend rather than tooling.

Suvoda has a real reputation for fast builds on complex protocols. 4G Clinical markets a protocol driven build approach specifically to shorten setup, and for a sponsor whose constraint is study start that matters more than any feature list. Endpoint Clinical and Signant Health both do this work competently at scale. Almac IXRS is a sensible choice when you already use Almac depot and packaging services, though that coupling is exactly what some sponsors want to avoid. Medidata and Calyx both offer a module that fits neatly beside their electronic data capture. These vendors exist because a common situation is real: one study, a fixed timeline, and no appetite to own a validated system.

License if most of this is true. One or two protocols in flight. A timeline to first patient in that nothing may jeopardise. No internal unblinded statistical function. No quality group that will own validation, periodic review and change control for years. A conventional design with fixed block randomization and simple trigger and top up resupply. That describes most sponsors, and telling you so costs us the larger project.

Where they stop: the operating model, not the capability

The complaint we hear is almost never about features. It is about how the relationship works.

Every protocol is a configuration project with a fee. A sponsor running fifteen similar protocols a year pays fifteen times for a design family they could describe in one paragraph. The vendor is not being unreasonable, because each study genuinely needs configuration and testing. The waste is that the same three parameter sets keep reappearing under different study numbers, and nobody is allowed to encode them once.

Mid study change is a change order with a queue position. An amendment adds a stratification factor. Sites in three time zones are enrolling continuously, so there is no window to take the system down anyway. The constraint on the change is rarely engineering hours. It is the vendor release process and where your request sits in it. Sponsors who have had an amendment delayed twice by that queue are the ones who call us.

The resupply algorithm is protocol specific and yours is not standard. Trigger and top up levels are fine until you have a titration design where the next visit consumes an unpredictable number of kits, a cohort escalation where a whole arm may stop, a seasonal enrollment pattern leaving stock idle while a new country opens empty, and a product with a short retest date where shipping early wastes supply that took nine months to manufacture. Encoding your two or three design families as parameterised strategies, so a new protocol is a configuration your own supply lead completes in a day, is the entire financial argument for building. It only works if you genuinely have a repeating design family. If every protocol is unlike the last, license.

The arithmetic: per study cost versus cost to build

Vendors price per study: a setup fee reflecting protocol complexity, then a monthly hosting and support charge across the study life, with change orders separate. The all in figures we see modelled land between roughly $120,000 and $300,000 per study, and a complex platform trial sits above that.

Take $180,000 as a working midpoint. A platform build landing at $550,000, plus about $110,000 for the validation package, plus roughly $95,000 a year to run and maintain it, totals near $1,040,000 over five years. A build does not remove per study work either: configuration and user acceptance testing per protocol still costs something internally, call it $45,000. So each study saves about $135,000, and the crossover sits at roughly eight studies over five years, which is under two protocols a year.

Now the awkward part. That number says almost every repeat sponsor should build, and we still tell most of them to license. The money is not the binding constraint here. First patient in is, and so is whether you have the unblinded statistical function and the quality group to own a validated safety critical system for its whole life. If either is missing, the arithmetic is irrelevant.

What a custom RTSM build actually costs

A first release with randomization and stratification, kit assignment, site and depot inventory, trigger based resupply, emergency unblinding and the validation package runs $130,000 to $260,000 and ships in 16 to 24 weeks. A full platform adding supply simulation, expiry and retest handling, country release and import rules, excursion quarantine, drug accountability and reconciliation, a configuration library and site facing interfaces runs $350,000 to $800,000 phased across 10 to 18 months.

Three lines to budget explicitly. Qualification effort sits at 20 to 30 percent on top of engineering, because this is regulated computerised system territory under 21 CFR Part 11 and EU Annex 11, with GAMP 5 as the framework, requirements traced to executed test scripts, and installation, operational and performance qualification. A quote that omits it is incomplete rather than cheap. Migrating and reconfiguring existing studies runs 10 to 25 percent of the build. Year two onward runs 15 to 20 percent of build cost annually, and in this category that includes periodic review, which is not optional.

What pushes it up: the number of design families, since each randomization scheme is real work. Depot and third party logistics integrations, because every provider file format is its own project. Multi language site interfaces with validated translations. Integration with electronic data capture and your safety system. What holds it down: one design family implemented properly and two live studies run on it before widening scope.

The four situations where building wins

Regulatory fit. Good Clinical Practice moved to ICH E6(R3), and the European Union Clinical Trials Regulation 536/2014 runs submissions through the Clinical Trials Information System with its own labelling requirements for investigational medicinal products. Suspected unexpected serious adverse reactions carry hard clocks: seven days for fatal or life threatening cases, fifteen for others. When your own quality system, your country release map and those calendars all have to agree inside one system, owning the configuration is worth more than owning the features.

Scale economics. Above the crossover in the arithmetic above, once per study configuration fees have become a visible budget line rather than a project cost nobody aggregates.

A workflow that is your competitive advantage. Supply simulation. Monte Carlo runs over enrollment scenarios, dropout, titration behaviour and shipping lead times answer how much overage you actually need and where to hold it. That is a solved statistical problem, it drives manufacturing decisions worth far more than the software, and it depends on your own historical enrollment data. Anyone selling artificial intelligence randomization is selling a risk you cannot explain to an inspector.

Integration sprawl across three or more systems. Electronic data capture, your safety database, your own depot network or third party logistics provider, the labelling system and the clinical trial management system. Sponsors with their own supply operation feel this hardest, because the assignment layer and the inventory truth sit in different companies.

How to decide in a week

Two tests, both cheap, and together they answer the question better than a procurement exercise.

Monday and Tuesday: pull your last three mid study amendments. For each, record the date the change was requested, the date it went live, and the change order fee. Then list what the study team did in the gap, because the workaround is usually a manual process at sites that nobody wrote down.

Wednesday: lay your last six protocols side by side and mark the randomization scheme, the stratification factors and the resupply strategy for each. Count how many distinct design families you actually run. If it is two or three, you have the precondition for building. If it is six, you do not.

Thursday: rehearse an emergency unblinding at an inconvenient hour with your current system, with the site on a poor connection. Time it. Check what got recorded and who was notified.

Friday: decide. Amendments delayed more than once, two or three repeating design families, and a quality group willing to own validation means build. Anything else means license, and license well.

Then pay for a discovery phase rather than taking a free estimate. At Digital Heroes that produces a signed product requirements document before any code is written: the allocation and blinding architecture including query layer separation, the resupply strategy parameters, the country release and expiry model, the unblinding path, the validation plan and the acceptance criteria. You own it whether you build with us, run a procurement against it, or hand it to Suvoda.

Who we are wrong for: a sponsor with one pivotal study and a fixed start date, and any organisation without a quality function to own a validated system. We fit repeat sponsors with a repeating design family and their own supply operation. More than fifty specialists, over 2,000 projects delivered, and a named team you meet before signing. Our India LLP, US LLC and UK LTD entities mean the intellectual property and the validation package assign under your own law. Checkable on Clutch, Trustpilot, Fiverr Vetted Pro and D-U-N-S.

Book a 30-minute call with Digital Heroes and get a written plan and a fixed quote within 48 hours.